ARMATA PHARMACEUTICALS, INC. Variable Lease, Payment
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Variable Lease, Payment of $400.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:VariableLeasePayment · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. variable lease, payment for the quarter ending 2026-06-30 was $400.00K, a 20.00% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. variable lease, payment for the quarter ending 2025-12-31 was $300.00K, a 0.00% change year-over-year.
- ARMATA PHARMACEUTICALS, INC. variable lease, payment for the quarter ending 2025-09-30 was $400.00K, a 0.00% change year-over-year.
- ARMATA PHARMACEUTICALS, INC. variable lease, payment for the quarter ending 2025-06-30 was $500.00K, a 25.00% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. variable lease, payment for fiscal 2025 was $1.50M, a 11.76% decline from fiscal 2024.
- ARMATA PHARMACEUTICALS, INC. variable lease, payment for fiscal 2024 was $1.70M, a 70.00% increase from fiscal 2023.
- ARMATA PHARMACEUTICALS, INC. variable lease, payment for fiscal 2023 was $1.00M.
| Period end | Variable Lease, Payment 3 month | Variable Lease, Payment 6 month | Variable Lease, Payment 9 month | Variable Lease, Payment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $400.00K 10-Q · filed 2026-08-12 | $700.00K 10-Q · filed 2026-08-12 | ||
| 2025-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $700.00K derived: sum of 2 quarters · filed 2026-03-25 | $1.20M derived: sum of 3 quarters · filed 2026-08-12 | $1.50M 10-K · filed 2026-03-25 |
| 2025-09-30 | $400.00K 10-Q · filed 2025-11-12 | $900.00K derived: sum of 2 quarters · filed 2026-08-12 | $1.20M 10-Q · filed 2025-11-12 | $1.50M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $500.00K 10-Q · filed 2026-08-12 | $800.00K 10-Q · filed 2026-08-12 | $1.10M derived: sum of 3 quarters · filed 2026-08-12 | $1.50M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $300.00K 10-Q · filed 2026-05-13 | $600.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.00M derived: sum of 3 quarters · filed 2026-05-13 | $1.40M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $700.00K derived: sum of 2 quarters · filed 2026-03-25 | $1.10M derived: sum of 3 quarters · filed 2026-03-25 | $1.70M 10-K · filed 2026-03-25 |
| 2024-09-30 | $400.00K 10-Q · filed 2025-11-12 | $800.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.40M 10-Q · filed 2025-11-12 | $1.50M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $400.00K 10-Q · filed 2025-08-12 | $1.00M 10-Q · filed 2025-08-12 | $1.10M derived: sum of 3 quarters · filed 2025-08-12 | $1.60M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $600.00K 10-Q · filed 2025-05-14 | $700.00K derived: sum of 2 quarters · filed 2025-05-14 | $1.20M derived: sum of 3 quarters · filed 2025-05-14 | $1.40M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $600.00K derived: sum of 2 quarters · filed 2025-03-21 | $800.00K derived: sum of 3 quarters · filed 2025-03-21 | $1.00M 10-K · filed 2025-03-21 |
| 2023-09-30 | $500.00K 10-Q · filed 2024-11-13 | $700.00K derived: sum of 2 quarters · filed 2024-11-13 | $900.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $200.00K 10-Q · filed 2024-08-13 | $500.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $300.00K 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |